Interfering with interferon: Re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence

Liver Transplantation

Volumn 14, Issue 3, 2008, Pages 265-267

  Watashi, Koichi ^a,b   Metselaar, Herold J ^c   van der Laan, Luc J W ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CYCLOPHILIN; CYCLOSPORIN A; DOUBLE STRANDED RNA; GLUCOCORTICOID; IMMUNOPHILIN; INTERFERON; INTERLEUKIN 2; JANUS KINASE 2; PEGINTERFERON ALPHA; PROTEIN KINASE R; RIBAVIRIN; STAT1 PROTEIN; STAT2 PROTEIN; STEROID; TACROLIMUS;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DRUG BINDING; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG POTENTIATION; EDITORIAL; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; RECURRENT INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CALCINEURIN; CYCLOSPORINE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERFERONS; RECURRENCE; SIGNAL TRANSDUCTION; TACROLIMUS; VIRUS REPLICATION;

EID: 41149173637     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21363     Document Type: Editorial

References (19)

1. Hirano K, et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporine A, on interferon induced anti-viral proteins in human hepatocyte cells. Liver Transpl 2008; 14:292-298.
2. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002, 8, S19-S27.
3. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38: 1282-1288.
4. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42-47.
5. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, Shimotohno K. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 2006;343:879-884.
6. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51-57.
7. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131:1452-1462.
8. Ishii N, Watashi K, Hishild T, Goto K, Inoue D, Hijikata M, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 2006;80:4510-4520.
9. Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43:761-770.
10. Sandborn WJ, Lawson GM, Krom RA, Wiesner RH. Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection. Hepatology 1992; 15:1086-1091.
11. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-122.
12. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-1041.
13. Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12: 1464-1472.
14. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006;12:762-767.
15. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-714.
16. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-572.
17. Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation 2006,82:579-580.
18. Trajkovic V, Badovinac V, Jankoviá V, Samardzic T, Maksimović D, Popadić D. Cyclosporin A suppresses the induction of nitric oxide synthesis in interferon-gamma-treated L929 fibroblasts. Scand J Immunol 1999;49:126-130.
19. Hu X, Li WP, Meng C, Ivashkiv LB. Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol 2003; 170:4833-4839.